Innovent Advances IBI363 Into Phase III Colorectal Cancer Trial
San Francisco, USA and Suzhou, China, August 6, 2026 Innovent Biologics has completed dosing of the first patient in...
IBI363
Advertisement
Innovent’s IBI363 Shows Strong First-Line NSCLC Data
SAN FRANCISCO and SUZHOU, China, May 22, 2026 Innovent Biologics announced encouraging preliminary Proof-of-Concept (PoC) clinical data for IBI363,...
Innovent IBI363 Shows Strong Survival in NSCLC
SAN FRANCISCO and SUZHOU, China, May 21, 2026 Innovent Biologics, Inc. announced updated long-term clinical data from the Phase...
GSK Partners With SBP Group to Expand Hepatitis B Treatment
LONDON, UK – May 11, 2026 GSK plc announced an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group) through...
Innovent Secures Third NMPA Breakthrough Status for IBI363
SAN FRANCISCO and SUZHOU, China, May 10, 2026 Innovent Biologics, Inc. announced that China’s National Medical Products Administration (NMPA)...
Advertisement
